ISB News

‘Demystifying Disease, Democratizing Health Care’

In the Feb. 26, 2014, issue of Science Translational Medicine, Dr. Lee Hood and Dr. Nathan Price, of Institute for Systems Biology, deliver an editorial stating the vision of the 100K Wellness Project. The project will track health-related data types for 100K individuals longitudinally over the course of 20-30 or more years.

"Unsustainable cost increases threaten the global health care system, and further progress is stymied more by societal than technological factors. Only by engaging health care consumers (that is, patients) as pioneers who provide both health-related data and insights into pathophysiology can we meet these societal challenges and thus accelerate the pace of biomedical innovation. "

– Drs. Lee Hood and Nathan Price, Science Translational Medicine

To read the full editorial, please visit Science Translational Medicine or download the PDF.

To learn more about the 100K Wellness Project, please visit our research site.

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.